Research Field

In recent years, there is growing interest in the clinical therapeutic effects of anti-cancer drugs using immune checkpoint inhibitors and CAR-T cells in the immuno-oncology field. Many studies have focused on the mechanisms. Especially, elucidating immune avoidance mechanisms in the tumor microenvironment and developing targets is essential to overcome the limitation of immune-oncology drugs. Our laboratory intensively investigates the mechanism of immune rejection in both allografts and xenografts using animal models, tissues, cells, and molecule levels to identify immune activation and tolerance mechanisms. On the contrary, we are looking for a way to regulate immune avoidance mechanisms in tumor microenvironments for a therapeutic approach. To overcome the limitations of immune checkpoint inhibitors and CAR-T cell therapy, we are developing immune checkpoint activators that can convert cold tumors into hot tumors.

Pure Link

Keyword

Immune tolerance, Regulatory T cell, Exosome, CAR-Treg, CyTOF, scRNAseq, Spatial transcriptomics, Clinical immunology, Immunophenotype